This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Company News for Oct 31, 2025
by Zacks Equity Research
Companies in The News Are: WDC,LLY,IP,CAH
Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales
by Zacks Equity Research
Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year sales and earnings outlook.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge
Pre-markets Down on Questions: Fed, Jobs & Q3 Earnings
by Mark Vickery
Weekly Jobless Claims are not out again this Thursday morning, for the fifth straight week.
Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Eli Lilly (LLY) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of +16.61% and +9.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
5 Key Earnings Charts to Watch
by Tracey Ryniec
Look beyond big technology at stocks in other areas like big pharma, infrastructure, energy and aerospace.
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
by Sundeep Ganoria
LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and fuel long-term growth.
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
by Kinjel Shah
Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.
INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales
by Zacks Equity Research
Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.
Is It Worth Investing in Lilly (LLY) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
5 of 7 Mega-Caps Report: Global Week Ahead
by John Blank
Mega-cap tech and growth company earnings reports headline a massive week of U.S. corporate results that could shed light on the state of the effervescent "AI trade."
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
by Ahan Chakraborty
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings
by Kinjel Shah
Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the pressure of pricing and competition.
Seeking Clues to Lilly (LLY) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
by Sundeep Ganoria
Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.
Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs
by Aparajita Dutta
Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs.
Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
by Sundeep Ganoria
LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.
Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.
Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?
by Ahan Chakraborty
Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.
NVO Stock Falls Amid Governance Shift as Foundation Seeks New Board
by Zacks Equity Research
Novo Nordisk stock slides as the Novo Nordisk Foundation pushes a sweeping board overhaul, signaling a new era in governance and strategic direction.
Eli Lilly (LLY) Stock Moves -1.16%: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) reached $799.57 at the closing of the latest trading day, reflecting a -1.16% change compared to its last close.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.